Clinical trial disruption concerns related to the COVID-19 pandemic topped across various geographies as the outbreak delayed or led to the suspension of enrolment for such trial programmes across the globe.
GlobalData conducted a poll to identify primary business concerns related to coronavirus outbreak in North America, Europe, Asia Pacific and Rest of the World (RoW).
Primary Business Concerns Related to the Covid-19 Outbreak by Geography
Clinical trial disruption was the primary business concern according to a majority 28% of the respondents in Europe. The same opinion was shared by 26% of the respondents in North America, 26% in RoW and 20% in Asia Pacific.
Around 21% of the companies in North America noted that the safety of the patients recruited in the trials is their biggest concern. The figure stood at 20% in Europe, 16% in Asia Pacific and 14% in RoW.
Employee safety emerged as a major concern in Asia Pacific and RoW, according to 20% of the respondents each who expressed their apprehension about the well-being of their staff amid the pandemic. In Europe and North America, the figure stood at 16%.
The survey also found that concerns related to contract research organisations (CRO) disruptions are higher in Europe (14%) and North America (12%) than in Asia Pacific (7%) and RoW (6%).
Furthermore, the percentage of respondents who felt that the impact on supply chains is of the highest concern stood at 17% in RoW, 16% in Asia Pacific, 11% in North America and 8% in Europe.
Approximately 14% of the respondents in Asia Pacific opined that business development is the main concern, followed by 10% in North America, 8% in Europe and 6% in RoW.
Capital raising concerns were highest among respondents from the RoW (11%), followed by Asia Pacific (7%), North America (4%) and Europe (3%).
The analysis is based on responses received for Coronavirus Survey – COVID-19 and Decentralised Clinical Trials conducted by GlobalData between 04 June and 22 June 2020.